Agreement - August 13, 2026
Zealand Pharma enters into royalty purchase and sale agreement with Royalty Pharma
Zealand Pharma has entered into a royalty purchase and sale agreement with Royalty Pharma in exchange for Zealand Pharma’s economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.
Agreement - August 10, 2026
Sobi enters strategic partnership with Innate Pharma
Swedish Orphan Biovitrum and Innate Pharma have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL).
Agreement - July 14, 2026
AstraZeneca enters exclusive global license agreement with Dizal Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer.
Agreement - July 14, 2026
Prolight signs development agreement with BRAINBox
Prolight Diagnostics has announces the successful completion of a 260-patient feasibility study and the subsequent signing of a development agreement with BRAINBox Solutions.
Agreement - July 3, 2026
AlzeCure enters an out-licensing and collaboration agreement with QuantumCell
AlzeCure Pharma has entered into an out-licensing and collaboration agreement with QuantumCell, a Danish tech-enabled biotech company, regarding the global rights to AlzeCure’s Alzheimer’s platform NeuroRestore, including the leading drug candidate ACD856.
Agreement - June 22, 2026
BioArctic and Lilly sign research and collaboration agreement
The company has entered into the agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration.